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Drugs that inhibit growth of tumours and their blood supply could have considerable therapeutic potential. 2-Methoxyoestradiol-
3,17-O,O-bis-sulphamate (2-MeOE2bisMATE) has been shown to inhibit the proliferation of MCF-7 (ER+) breast cancer cells and
angiogenesis in vitro. 2-MeOE2bisMATE and its analogue, 17-Cym-2-MeOE2MATE, were investigated for their ability to inhibit in vivo
angiogenesis and tumour growth. The mouse Matrigel plug assay for angiogenesis was used to investigate the effect of compounds on
neovascularisation and was quantified using a FITC-dextran injection technique. Nude mice bearing tumours derived from MCF-7
cells were used to assess efficacy on tumour growth. Tumour sections were stained for VEGFR-2 and Ki67 to assess tumour
angiogenesis and cell proliferation respectively. Matrigel plugs supplemented with basic fibroblast growth factor resulted in increased
neovascularisation over 7 days. Oral administration of 2-MeOE2bisMATE for 7 days at 10 or 50mgkg
 1 significantly reduced
neovascularisation to or below control levels respectively. 17-Cym-2-MeOE2MATE at 20mgkg
 1 was equally effective. 2-
MeOE2bisMATE, dosed daily for 21 days, caused a 52% reduction in tumour growth at 5mgkg
 1 and 38% regression at 20mgkg
 1.
17-Cym-2-MeOE2MATE (20mgkg
 1) reduced tumour growth by 92%. Immunohistochemistry revealed a reduction in angiogenesis
and proliferation. Matrigel plug and tumour imaging after FITC-dextran injection indicated that 2-MeOE2bisMATE caused a marked
disruption of vasculature. These sulphamoylated oestrogen derivatives have been shown to be potent inhibitors of angiogenesis in
vivo. This, together with their ability to inhibit tumour growth, indicates the potential of this new class of drugs for further
development for cancer therapy.
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The development of angiogenesis inhibitors, which block the
formation of new blood vessels, offers a novel therapeutic
approach to inhibit tumour growth (Folkman, 1992). A number
of anti-angiogenic drugs have now been developed and tested in
clinical trials (Harris, 1997; Zhang and Harris, 1998). So far, the use
of anti-angiogenic agents to inhibit tumour growth has met with
only limited success. In a recent study, a monoclonal antibody
against vascular endothelial growth factor (VEGF), bevacizumab,
in combination with chemotherapy resulted in an improvement in
survival in patients with colorectal cancer (Hurwitz et al, 2004).
This suggests that to obtain the best results with anti-angiogenic
drugs they will need to be used in conjunction with cytotoxic
agents. Support for this concept has emerged from studies in
which chemotherapeutic agents are administered in a metronomic
low-dose schedule in an attempt to combine their anti-proliferative
and anti-angiogenic activities (Vacca et al, 1999; Hanahan et al,
2000). Over the last decade there has been considerable interest in
the natural oestrogen metabolite, 2-methoxyoestradiol (2-MeOE2,
Figure 1, 1) as a potential drug for cancer therapy (Seegers et al,
1989; Fotsis et al, 1994; Klauber et al, 1997; Brem, 1998; Zhu and
Conney, 1998a,b; Lakhani et al, 2003; Dahut et al, 2006). This
compound not only inhibits the proliferation of cancer cells in
vitro and tumours in vivo but also displays anti-angiogenic activity
(Fotsis et al, 1994; Klauber et al, 1997). 2-MeOE2 is currently in
phase I/II trials for the treatment of breast and prostate cancer but
relatively high doses (up to 6gday
 1) are used (Dahut et al, 2006).
The reason for this is that 2-MeOE2 has a very low bioavailability
and is rapidly inactivated by conjugation and oxidation of the
hydroxyl groups at the C3/C17 positions of the oestrane nucleus
(Liu et al, 2005; Newman et al, 2006). Furthermore, 2MeOE2 has
been shown to exhibit mitogenic effects in ER-positive cells that
were mediated through the oestrogen receptor (Liu and Zhu,
2004). Numerous analogues of 2-MeOE2 have been synthesised
and tested in an attempt to improve its potency including the
2-ethoxy, 2-methoxymethyl and 14-dehydro derivatives (Cushman
et al, 1995; Brueggemeier et al, 2001; Tinley et al, 2003). However,
all these analogues retain the C3/C17 hydroxy groups of 2-MeOE2
and it is likely that they, like 2-MeOE2, will be rapidly inactivated
in vivo.
As an alternative approach to modification of either the steroid
nucleus or the C2 position of 2-MeOE2, the C3/C17 hydroxy
groups were sulphamoylated to give 2-methoxyoestradiol-3,17-
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sO,O-bis-sulphamate (2-MeOE2bisMATE, Figures 1, 2) (Howarth
et al, 1994; Purohit et al, 1995a,b; Raobaikady et al, 2003; Newman
et al, 2004; Leese et al, 2006). In addition, a C17 analogue of
2-MeOE2bisMATE, cyanomethyl derivative (2-methoxy-3-O-sulpha-
moyl-17b-cyanomethyloestra-1,3,5(10)-triene,17-Cym-2-MeOE2-
MATE, Figures 1, 3) was also synthesised (Utsumi et al, 2005).
2-MeOE2bisMATE was previously shown to inhibit angiogenesis in
two in vitro assays (Newman et al, 2004). It inhibited the
proliferation of human umbilical vein endothelial cells (HUVECs),
used as a marker of angiogenesis, with the bis-sulphamate being
60-fold more potent than 2-MeOE2. In addition, using an
endothelial cell/fibroblast co-culture model of in vitro angiogenesis
the bis-sulphamoylated derivative was 13-fold more potent at
inhibiting tubule formation than 2-MeOE2 (Newman et al, 2004).
2-MeOE2bisMATE has therefore been shown to be a potent
inhibitor of in vitro angiogenesis but, as yet, no studies have been
carried out to examine its potential to inhibit angiogenesis in vivo.
In the present study its ability, and that of 17-Cym-2-MeOE2-
MATE, to inhibit angiogenesis in vivo has been investigated using
the Matrigel plug angiogenesis model in C57BL/6J mice. In
addition to its anti-angiogenic properties, 2-MeOE2bisMATE also
inhibits the growth of oestrogen receptor positive (ER+) and
negative (ER ) cells (Utsumi et al, 2005). It was 10-fold more
potent than 2-MeOE2 at inhibiting the proliferation of MCF-7 ER+
breast cancer cells in vitro (Newman et al, 2004). Its ability to
inhibit the growth of xenografts derived from MCF-7 breast cancer
cells was therefore also examined in the present study. Tumours
obtained from these animals were further examined for evidence
that these compounds could inhibit tumour angiogenesis.
MATERIALS AND METHODS
Compound and synthesis
2-MeOE2, 2-MeOE2bisMATE, 17-Cym-2-MeOE2MATE and its
non-sulphamoylated derivative (2-methoxy-3-hydroxy-17b-cyano-
methyl oestra-1,3,5 (10)-triene, 17-Cym-2-MeOE2, Figures 1, 4)
were synthesised as described previously (Leese et al, 2005, 2006;
Utsumi et al, 2005). All compounds exhibited spectroscopic and
analytical data in accordance with their structure and were pure, as
shown by high-performance liquid chromatography.
In vitro cell proliferation
The human breast carcinoma cell line MCF-7 (ERþ) was obtained
from the American Type Culture Collection (LGC Promochem,
Teddington, UK) and maintained in Dulbecco’s minimal essential
medium containing phenol red, supplemented with 10% fetal calf
serum and antibiotics (Sigma, Poole, Dorset, UK). Cells were
cultured at 371C under 5% CO2 in a humidified incubator.
Matrigel plug assay
The Matrigel plug assay was a modified version of the methods
described previously (Passaniti et al, 1992; Prewett et al, 1999).
Briefly, female C57BL/6J mice (6–8 weeks old) were obtained from
Charles River UK Ltd (Margate, Kent, UK). Animals were
maintained in positive pressure isolators under a 12h light–dark
cycle and allowed access to food and water ad libitum. The
experiments were approved by the Imperial College Animal Ethical
Review Committee and met the standards required by the
UKCCCR guidelines (Workman et al, 1998). Mice were anaes-
thetised, placed on a heated pad (371C) and injected subcuta-
neously, into the flanks with 0.5ml ice-cold Matrigel (Becton
Dickinson, Oxford, Oxon, UK) supplemented with 500ng basic
fibroblast growth factor (bFGF; R&D Systems, Oxford, Oxon, UK).
Control mice were injected with Matrigel without bFGF. Before the
end of each study vascularisation of Matrigel was quantified by
injecting mice with FITC-dextran (125000 molecular weight,
Sigma), 0.1ml of a 0.25mgml
 1 solution intravenously (i.v.),
which allowed blood vessels within plugs to be visualised. Animals
were killed 20min after injection, when Matrigel plugs were
removed and photographs showing the extent of vascularisation
taken using a dissecting microscope (Nikon SMZ1500). Photo-
graphs of blood vessels within Matrigel plugs were also obtained
using a microscope with a fluorescent light source (Zeiss-Axiovert
200). Quantification of FITC-dextran in the Matrigel plugs was
achieved by incubating plugs in 1ml Dispase reagent (Becton
Dickinson) for 16h at 371C. The resulting mixture was centrifuged
in a microfuge at 13000r.p.m. for 30s. The fluorescence of the
resulting supernatants was measured using a fluorimeter (Fluostar
plus Optima, BCG, Bucks, UK), excitation at 480nm, measurement
at 520nm, and quantitated against a standard curve of FITC-
dextran (0.4–25mgml
 1).
A preliminary study was carried out to determine the time for
optimal neovascularisation of Matrigel plugs to develop. For this
plugs were removed from control mice (no added bFGF) at the end
of days 7, 10 and 14 and from mice where plugs contained bFGF at
the end of days 1, 2, 4, 7, 10 and 14 after Matrigel injection. Having
determined the optimal time for neovascularisation, a dose–
response study using 2-MeOE2 or 2-MeOE2bisMATE was
performed in which these compounds were administered daily at
1, 10 or 50mgday
 1, per os, (p.o.) (in tetrahydrofuran:propylene
glycol, THF:PG, 1:9, v/v), daily for 7 days. At the end of the study,
Matrigel plugs were removed for visualisation and quantification.
After identifying doses of 2-MeOE2 and 2-MeOE2bisMATE that
inhibited vascularisation the number of doses to inhibit neovas-
cularisation (preventative study) or disrupt established vasculature
(treatment study) was investigated. For the preventative study
mice were dosed with compounds (50mgkg
 1, p.o.) for 1–4 days
24h after Matrigel injection. Seven days after injection of the
Matrigel plugs mice were killed and the plugs removed for
visualisation and quantification. For the treatment study, neo-
vascularisation was allowed to develop over a 7-day period. Groups
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H
H
H
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Figure 1 Structure of compounds. Compound 1, 2-methoxyoestradiol
(2-MeOE2); compound 2, 2-methoxyoestradiol-3,17-O-O-bis-sulphamate
(2-MeOE2bisMATE); compound 3, 2-methoxy-3-O-sulphamoyl-17b-cya-
nomethyl oestra-1, 3, 5 (10)-triene (17-Cym-2-MeOE2MATE); compound
4, 2-methoxy-3-hydroxy-17b-cyanomethyl oestra-1, 3, 5 (10)-triene (17-
Cym-2-MeOE2).
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sof animals were dosed with compounds on day 8 (1-day dosing) or
days 8–10 (3 days of dosing) at 50mgkg
 1, p.o. The effects on
established vasculature were assessed 14 days after the injection of
the Matrigel plugs.
A study was also carried out to compare the anti-angiogenic
properties of 2-MeOE2bisMATE with that of 17-Cym-2-MeOE2-
MATE and its non-sulphamoylated derivative 17-Cym-2-MeOE2.
For this, compounds (20mgkg
 1, p.o.) were administered daily for
4 days with plugs being removed for visualisation and quantifica-
tion on day 8.
MCF-7 tumour xenograft model
MCF-7 breast cancer cell tumours were established by inoculating
cells subcutaneously (10 10
6 cells in 0.1ml growth factor-reduced
Matrigel) into female athymic (nu/nu) mice (Harlan, Oxford,
Oxon, UK). The growth of these hormone-dependent tumours
was stimulated by the implantation of oestradiol-slow
release pellets (0.52mg, 60-day release; Innovative Research of
America, Sarasota, FL, USA) 24h before cell inoculation. When
tumours had reached 100mm
3 in volume animals were dosed
orally with vehicle (THF:PG 1:9, v/v), 2-MeOE2 (20mgkg
 1),
2-MeOE2bisMATE (5 and 20mgkg
 1) or 17-Cym-2-MeOE2MATE
(5 and 20mgkg
 1) daily for 5 days per week for 3 weeks. Tumour
volumes were measured weekly with callipers and tumour volumes
calculated using the formula lw
2/2 (where l is the length and
w is the width) with results being expressed as the percentage
change in tumour volumes after 1, 2 or 3 weeks of dosing
compared with tumour volumes at the start of dosing. At the end
of the study, some mice (n¼3) were injected i.v. with FITC-
dextran (0.1ml of 0.25mgml
 1) 20min before the animals were
killed. Blood vessels in tumours were visualised, photographed and
tumour angiogenesis quantified as described previously for
Matrigel plugs.
As oestrogen sulphamates are potent inhibitors of steroid
sulphatase (STS), its activity was measured in samples of tumour
and liver tissues from control and treated animals as described
previously (Purohit et al, 1995a,b).
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Figure 2 (A) Time course for neovascularisation in Matrigel plugs. C57BL/J6 mice were injected subcutaneously with 0.5ml Matrigel with or without
(control) bFGF. Twenty minutes before removing plugs from mice FITC-dextran (0.1ml of a 0.25mgml
 1 solution) was injected i.v. to facilitate visualisation
and quantification of angiogenesis. Plugs were removed on days 2–14 after injection (means7s.e.m., n¼5, *Po0.05; ***Po0.001 compared with
corresponding controls). (B) Effect of 2-MeOE2 and 2-MeOE2bisMATE on Matrigel plug neovascularisation. Compounds were administered orally at the
doses indicated for 7 days starting 24h after Matrigel injection. On day 8 FITC-dextran was injected 20min before removal of plugs from mice as described
above. Representative photographs are shown from five mice per group. (C) Quantification of angiogenesis within the Matrigel plugs was achieved after
FITC-dextran injection (means7s.e.m., n¼5, *Po0.05, ***Po0.001 compared with the level of vascularisation in Matrigel plugs supplemented with bFGF
in animals receiving vehicle only, NS, nonsignificant).
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sTumour histology
Tumours derived from MCF-7 cells from mice were immediately
frozen and used to prepare cryostat sections (0.6mm) for
immunohistochemical analysis. Sections were stained for Ki67, a
marker for cell proliferation, using an anti-Ki67 antibody (AbCam,
Cambridge, Cambs, UK) with an ABC complex and chromogen
kit which yielded a red stain when positive. The effect of the
compounds on angiogenesis was assessed by staining for VEGFR-2
(AbCam), a marker for endothelial cells (Matthews et al, 1991;
Terman et al, 1992). For this, sections were stained using a human
VEGFR-2 antibody with a streptavidin peroxidase system with
subsequent haemotoxylin counterstaining. Quantification of sec-
tions was achieved by subtracting the background staining from
the specific staining using image analysis software (Image J, NIH,
Bethesda, MD, USA) developed by the NIH that measures the
number of stained pixels/field, selected from three random fields
from three samples for each treatment group. Isotype control
staining was carried out for all specimens.
Statistics
Data were analysed for statistical significance using Student’s t-test
or analysis of variance (ANOVA).
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Figure 3 (A) The effect of dosing with 2-MeOE2bisMATE (50mgkg
 1, p.o.) for 1–4 days on neovascularisation of Matrigel plugs. After dosing for 1–4
days plugs were removed on day 7 after Matrigel injection. FITC-dextran was used as described previously to facilitate visualisation and quantification of
angiogenesis. Representative photographs of plugs from groups of five animals are shown. (B) Quantification of angiogenesis within Matrigel plugs shown in
(A) after FITC-dextran injection (means7s.e.m., n¼5, ***Po0.001 compared with bFGF). (C) The effect of dosing with 2-MeOE2bisMATE (50mgkg
 1,
p.o.) on established Matrigel plug vasculature. Neovascularisation was allowed to develop for 7 days before animals were dosed for 1 day or daily for 3 days.
Plugs were removed at end of day 14 for photography and quantification after FITC-dextran injection. (D) Quantification of angiogenesis within Matrigel
plugs shown in Figure 3c after FITC-dextran injection (means7s.e.m., n¼5, *Po0.05 compared with bFGF; NS, nonsignificant).
In vivo inhibition of angiogenesis
SK Chander et al
1371
British Journal of Cancer (2007) 96(9), 1368–1376 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sRESULTS
Inhibition of vascularisation in Matrigel plugs
An initial study was carried out to determine the time required for
optimal neovascularisation of Matrigel plugs containing bFGF. As
shown in Figure 2A, for animals injected with Matrigel lacking
bFGF, minimal vascularisation was seen and there was no increase
in the level of FITC-dextran fluorescence in plugs retrieved from
animals over a 7–14-day period. In contrast, plugs containing
bFGF revealed a marked degree of neovascularisation with a
maximum increase (116%, Po0.001) being achieved by day 7 after
plug injection. No further increases were detected on leaving the
plugs in animals for up to a further 7-day period. A preliminary
study was carried out in which VEGF was added to the Matrigel in
addition to bFGF but this did not increase the level of
neovascularisation seen above that resulting from the use of bFGF
alone (data not shown).
To examine the ability of 2-MeOE2 or 2-MeOE2bisMATE to
inhibit bFGF-induced plug neovascularisation mice were dosed
orally with these compounds for 7 days, starting 24h after Matrigel
injection. Visual inspection of the plug after removal revealed the
marked increase in vascularisation, seen as a deep red appearance
that occurred in plugs of untreated animals (Figure 2B).
For animals dosed with 2-MeOE2 (50mgkg
 1) or 2-MeOE2bis-
MATE (10 and 50mgkg
 1) there was a marked reduction in
the level of neovascularisation. Quantification of angiogenesis
revealed modest inhibitory effects of 2-MeOE2 (20 and 43% at 1
and 10mgkg
 1 respectively; NS) but a significant (83%, Po0.05)
reduction at the highest dose tested (Figure 2C). The effect of
2-MeOE2bisMATE on neovascularisation was much greater than that
of 2-MeOE2. At 10mgkg
 1 a similar reduction (87%, Po0.05) was
detected to that resulting from dosing animals with 50mgkg
 1 of
2-MeOE2. At the highest dose of 2-MeOE2bisMATE tested the level
of angiogenesis in plugs was below that detected in control animals
(Po0.001). At both 10 and 50mgkg
 1 doses, 2MeOE2bisMATE
significantly inhibited bFGF-induced angiogenesis compared with
2MeOE2.
Having established that a dose of 50mgkg
 1 2-MeOE2bisMATE
effectively abolished Matrigel plug neovascularisation, this dose
was used to investigate the number of doses required to prevent
neovascularisation (preventative study) or to disrupt established
blood vessels (treatment study), as would be encountered in a
therapeutic setting. As shown in Figure 3A and B, 7 days after
injection of Matrigel plugs a marked increase in neovascularisation
was detected on visual inspection and quantification. Administra-
tion of 2-MeOE2bisMATE daily for 1, 2, 3 or 4 days, 24h after
Matrigel injection, with removal of plugs 7 days after Matrigel
injection, revealed that dosing for 2 days was sufficient to
completely blocked plug vascularisation. After letting neovascular-
isation become established over a 7-day period dosing for 1 day
(i.e. day 8), followed by plug removal at end of the study on day 14,
resulted in a 44% reduction, with dosing for 3 days (i.e. days 8–10)
resulting in a 63% (Po0.05) reduction in plug vascularisation
(Figure 3C and D).
The efficacy of 2-MeOE2bisMATE in the Matrigel plug assay was
also compared with that of the cyanomethyl analogues (Figure 4).
Both 2-MeOE2bisMATE and 17-Cym-2-MeOE2MATE when admi-
nistered at 20mgkg
 1day
 1 daily for 4 days, 24h after Matrigel
injection, almost completely inhibited plug vascularisation (89 and
85% respectively, Po0.001). In contrast, the non-sulphamoylated
analogue, 17-Cym-2MeOE2, did not significantly reduce vascular-
isation at the dose tested.
Inhibition of MCF-7 tumour growth and angiogenesis
The ability of 2-MeOE2, 2-MeOE2bisMATE and 17-Cym-2-
MeOE2MATE to inhibit tumour growth was tested using
xenografts derived from oestradiol-stimulated MCF-7 cells
(Figure 5A). In the control group, tumour volumes increased by
300% over the 3-week period (Figure 5A). For mice receiving
2-MeOE2 (20mgkg
 1, p.o.) the growth of tumours did not differ
from that of animals in the control group. In contrast, dosing with
2-MeOE2bisMATE resulted in a significant reduction in tumour
volumes (52%, Po0.001) at the 5mgkg
 1 dose with a 38%
regression being detected at the 20mgkg
 1 dose (Po0.001). For
17-Cym-2-MeOE2MATE only the 20mgkg
 1 dose was effective,
reducing tumour growth by 92% (Po0.001) compared with
controls. Over the 3-week period for which animals were dosed
no significant changes in body weights were detected indicating a
lack of toxicity at the doses tested (data not shown). Quantification
of tumour angiogenesis by FITC-dextran injection revealed that
this decreased over the 3-week period by 4478% (Po0.05) after
dosing with 2-MeOE2bisMATE and 53715% (Po0.01) on dosing
with 17-Cym-2MeOE2MATE. STS activity in livers and tumours
was inhibited by 490% by both sulphamoylated compounds (data
not shown).
MCF-7 tumour histology
Histological examination of tumours obtained at the end of the
study revealed a high level of staining for the VEGFR-2 in control
animals (Figure 5B). Less specific staining was evident in sections
prepared from animals treated with 20mgkg
 1 of 2-MeOE2bis-
MATE or 17-Cym-2-MeOE2MATE. This was reflected in the
quantification of the VEGFR-2 staining, which revealed significant
decreases of 72% for 2-MeOE2bisMATE and 57% for 17-Cym-2-
MeOE2MATE (Figure 5C). At the 5mgkg
 1 doses these com-
pounds had minimal effect on VEGRF-2 expression. The decrease
in tumour growth and expression of VEGFR-2 resulting from
dosing with these compounds was associated with significant
decreases in tumour cell proliferation as indicated by the staining
and quantification of Ki67 (Figures 5D and E). At the 5mgkg
 1
dose both sulphamoylated compounds reduced Ki67 expression
(49–68%) in contrast to VEGFR-2, where a reduction in the level
of this receptor was only detected at the higher doses of the
compounds tested.
Visualisation of vasculature in Matrigel plugs and MCF-7
tumours
After establishing the FITC-dextran method to visualise
Matrigel plug vasculature this technique was further employed to
examine the effects of the sulphamoylated compounds on Matrigel
plug and tumour vasculature (Figure 6). Matrigel plugs
removed from the studies described above were routinely
photographed using a fluorescent microscope to visualise the
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Figure 4 Comparison of the in vivo anti-angiogenic efficacy of 2-
MeOE2bisMATE and 17-Cym-2-MeOE2MATE. Compounds (20mgkg
 1)
were administered orally, daily for 4 days, 24h after Matrigel injection, with
plug removal on day 7. FITC-dextran was injected 20min before plug
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with bFGF for animals receiving vehicle only; NS, nonsignificant).
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Figure 5 (A) Inhibition of growth of tumours derived from MCF-7 cells in nude mice. Animals were dosed orally with 2-MeOE2bisMATE or 17-Cym-2-
MeOE2MATE (5mgkg
 1 or 20mgkg
 1) or 2-MeOE2 (20mgkg
 1) 5 days per week for 3 weeks. Tumour volumes were measured weekly (means7s.e.m.,
n¼5-10, ***Po0.001 compared with controls; NS, nonsignificant). (B) Section of tumours were prepared and stained for VEGFR-2 ( 200 magnification;
scale bar, 1cm¼200mm)) as indicated by the arrows. (C) Quantification of staining for VEGFR-2 revealed that at 20mgkg
 1 both 2-MeOE2bisMATE and
17-Cym-2-MeOE2MATE significantly reduced the expression of this receptor (means7s.e.m., n¼3, *Po0.05, NS, nonsignificant). (D) Section of tumours
were prepared and stained for Ki67, a marker of cell proliferation ( 200 magnification). (E) Quantification revealed that at both doses tested a significant
reduction in Ki67 expression occurred (means7s.e.m., n¼3, **Po0.01, ***Po0.001 compared with control).
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sblood vessels. In this particular study, a Matrigel plug assay
was performed with 2MeOE2bisMATE at 40mgkg
 1, p.o. daily for
4 days and Matrigel plugs removed at the end of 7 days. Blood
vessels in the control bFGF supplemented plugs had a well-defined
branching structure indicative of a functioning capillary network
(Figure 6A). In plugs from animals receiving 2-MeOE2bisMATE,
the fluorescence associated with blood vessels was less intense with
evidence of vascular disruption (Figure 6B). In the MCF-7 breast
tumour xenograft model study a number of mice were injected
with FITC-dextran 20min before killing (see Materials and
Methods section for details). Tumours were removed and the
tumour vasculature visualised and photographed using a fluor-
escent microscope. In MCF-7 tumours obtained from untreated
animals, it was possible to see the blood vessel network within the
tumours (Figure 6C). In contrast, in tumours from animals treated
with 2-MeOE2bisMATE (20mgkg
 1, p.o. 5/7 days per week for 3
weeks), disruption of tumour vasculature was clearly evident
(Figure 6D).
DISCUSSION
The results from this study demonstrate that oral administration of
2-MeOE2bisMATE is able to block angiogenesis in vivo in the
mouse Matrigel plug model. At the highest dose tested neovascu-
larisation was below the background level detected in Matrigel
plugs not containing bFGF demonstrating the potency of this
compound as an anti-angiogenic agent. 2-MeOE2bisMATE caused
significant regression of tumour xenografts derived from MCF-7
breast cancer cells and reduced angiogenesis within these tumours.
17-Cym-2-MeOE2MATE also proved to be a potent inhibitor of
angiogenesis in the Matrigel plug model and also significantly
reduced the growth of MCF-7 xenografts at the higher dose tested
(20mgkg
 1). Thus, the 2-methoxy-3-O-sulphamoylated oestro-
gens are emerging as a class of compounds with greatly enhanced
in vivo efficacy relative to 2-MeOE2. 2-MeOE2 has previously been
shown to inhibit angiogenesis in vivo in xenografts derived from
B16 melanoma cells and MDA-MB-435 ER- breast cancer cells
(Fotsis et al, 1994; Klauber et al, 1997). In addition, the growth of
these tumours was also inhibited by oral administration of 2-
MeOE2 although relatively high doses (75–100mgkg
 1) were
required to reduce tumour growth. In the present study, dosing
with 2-MeOE2 at 50mgkg
 1 confirmed its ability to inhibit
angiogenesis in the Matrigel plug model, achieving a similar degree
of inhibition to that seen with 2-MeOE2bisMATE at 10mgkg
 1.
This suggests that 2-MeOE2bisMATE is at least five times more
potent than 2-MeOE2 at inhibiting in vivo angiogenesis. This is
consistent with results obtained from in vitro studies where 2-
MeOE2 was less effective at inhibiting the growth of HUVECs or
tubule formation in two in vitro models of angiogenesis (Newman
et al, 2004). Our compounds show potent activity at low doses
whereas 2MeOE2 at the same low dose is only weakly active.
However, higher doses of 2MeOE2 (Huh et al, 2006) do produce
similar effects to those observed with 2-MeOE2bisMATE and 17-
Cym-2-MeOE2MATE.
The superior efficacy of 2-MeOE2bisMATE and related com-
pounds over that of 2-MeOE2, raises important questions as to
why sulphamoylation increases the in vitro and in vivo potency of
this class of compound. It is evident that 2-MeOE2bisMATE is not
acting as a pro-drug for 2-MeOE2. In a metabolic study in rats, 2-
MeOE2 was not detectable in plasma for up to 24h after the oral or
i.v. administration of 2-MeOE2bisMATE (Ireson et al, 2004). It is
now known that sulphamoylated derivatives of oestrogens have a
superior pharmacokinetic profile and are more resistant to
metabolism than their non-sulphamoylated counterparts (New-
man et al, 2006). Oestrogen sulphamates, such as oestrone-3-O-
sulphamate (EMATE) were originally identified as potent STS
inhibitors, a property shared with 2-MeOE2bisMATE (Raobaikady
et al, 2005). EMATE was not developed for breast cancer therapy as
it became evident that oestrogen sulphamates had enhanced
oestrogenicity when administered orally to rats (Elger et al, 1995).
In a uterine weight gain assay, oestradiol sulphamate proved to be
five times more active than ethinyloestradiol and 100 times more
active than oestradiol, on oral application. The reasons for the
enhanced oestrogenicity associated with oestrogen sulphamates is
now known to result from their ability to be taken up into
erythrocytes where they bind to carbonic anhydrase II (Ho et al,
2003; Vicker et al, 2003). They transit the liver in the erythrocytes,
and are thus protected from first-pass inactivation, with sub-
sequent release into the systemic circulation. Support for such a
protective role for sulphamoylation was also obtained in the
present study in which the ability of 17-Cym-2-MeOE2MATE and
its non-sulphamoylated analogue were tested for their ability to
inhibit in vivo angiogenesis. Both of these compounds were
effective at inhibiting HUVEC growth and the formation of
microtubules in in vitro models of angiogenesis (unpublished
data). This contrasts with the results obtained in the present study
which demonstrated that while 17-Cym-2-MeOE2MATE was
equipotent with 2-MeOE2bisMATE at inhibiting Matrigel plug
vascularisation the non-sulphamoylated analogue, 17-Cym-2-
MeOE2, was much less effective at the same dose level. Thus, the
sulphamoylation of oestrogens having a 2-methoxy function is an
important mechanism for enhancing the potency and oral bioavai-
lability of this class of compound. In contrast to EMATE, 2-
MeOE2bisMATE and other compounds tested at 2000-fold higher
dose than oestrone are devoid of oestrogenic properties in ovariec-
tomised rats (data not shown) indicating lack of binding to ER.
In addition to inhibiting the neovascularisation of Matrigel
plugs both 2-MeOE2bisMATE and 17-Cym-2-MeOE2MATE proved
effective at inhibiting the growth of tumours derived from MCF-7
Matrigel plugs + bFGF 2-MeOE2bisMATE – 40 mg kg–1
Control – tumour 2-MeOE2bisMATE – 20 mg kg–1
AB
D C
Figure 6 (A) Matrigel plugs supplemented with bFGF were removed
from mice after FITC-dextran injection. The vasculature was visualised and
photographed using a fluorescent microscope. For animals receiving vehicle
only the intact vasculature was clearly visible. (B) For animals receiving 2-
MeOE2bisMATE (40mgkg
 1, p.o., daily for 4 days) marked disruption of
the vasculature occurred. (C) Studies with tumours derived from MCF-7
cells in nude mice after FITC-dextran injection revealed a well-established
vasculature in mice receiving vehicle. (D) For animals receiving 2-
MeOE2bisMATE (20mgkg
 1, p.o.) daily for 21 days disruption of tumour
vasculature was detected.
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scells in nude mice. At 20mgkg
 1, 2-MeOE2 did not inhibit the
growth of these tumours, a finding in keeping with results from in
vitro growth studies where 2-MeOE2bisMATE proved 10 times
more active than 2-MeOE2 (Newman et al, 2004). The reduction in
tumour growth was consistent with the 51–68% decrease in the
expression of Ki67. At 20mgkg
 1 2-MeOE2 had no effect on Ki67
expression (data not shown). At the doses tested, that is up to
20mgkg
 1 over a 3-week period, 2-MeOE2bisMATE and 17-Cym-
2-MeOE2 appeared to be devoid of any toxic effects as no
significant effects on animal weight was detected.
2-MeOE2bisMATE is thought to act like 2-MeOE2, by binding to
the colchicine-binding site on tubulin and altering microtubule
stability (MacCarthy-Morrogh et al, 2000; Raobaikady et al, 2005).
It induces Bcl-2 phosphorylation and apoptosis in endothelial and
cancer epithelial cells. It was recently reported that 2-MeOE2, by
disrupting microtubule stability, causes downregulation of the
pro-angiogenic transcription factor Hif-1a in PC3 and MDA-MB-
231 cancer cells with a subsequent reduction in VEGF production
(Mabjeesh et al, 2003). While VEGF levels were not measured in
the present study, 2-MeOE2bisMATE and 17-Cym-2-MeOE2MATE
were found to cause a significant reduction in the levels of one of
the VEGF receptors, VEGFR-2, however this is probably caused by
these compounds ability to reduce angiogenesis.
Additional experiments were carried out to examine if this class
of angiogenesis inhibitors only blocks the formation of new blood
vessels or whether they can also disrupt existing vasculature. For
this, animals were tested in a ‘preventative’ or ‘treatment’ setting as
described previously. Results from these studies clearly demon-
strate that 2-MeOE2bisMATE is able to almost completely block
neovascularisation of Matrigel plugs when given for 2–4 days after
Matrigel injection. After allowing neovascularisation to develop for
7 days, dosing for 1 or 3 days, with quantification at end of day 14,
revealed that 2-MeOE2bisMATE could significantly reduce estab-
lished vasculature, although to a lower degree than when given in
the preventative setting. Inspection of blood vessel structure in
Matrigel plugs and tumours revealed gross disruptions of the
vasculature. As tumours for these studies were obtained from
mice after dosing for a 3-week period these results suggest that
2-MeOE2bisMATE will be able to target established vasculature in
addition to inhibiting the neovascularisation process.
In summary, 2-MeOE2bisMATE and 17-Cym-2-MeOE2MATE
have been shown to be potent inhibitors of in vivo angiogenesis in
the mouse Matrigel plug assay. In addition, both compounds were
able to suppress the growth of xenografts derived from oestradiol-
stimulated MCF-7 cells in nude mice. Thus, these compounds have
a dual anti-proliferative, anti-angiogenic action that should
enhance their therapeutic efficacy. These compounds were at least
10 times more active than 2-MeOE2 at inhibiting the neovascular-
isation of Matrigel plugs indicating that sulphamoylation confers
significant additional potency to this class of compound. In view of
the potent anti-angiogenic and tumour growth inhibitory proper-
ties of this class of compounds, they should have considerable
therapeutic potential for the treatment of a wide range of cancers.
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